Jens Van Fraeyenhove
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jens Van Fraeyenhove has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Gilles W. De Keulenaer
University of Antwerp
2 shared publications - Alessandra Ghigo
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center “Guido Tarone”, University of Torino, Torino, Italy
1 shared publication Antoine A.F. de Vries
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
1 shared publicationArthur Bezerra
Department of Physics and Astronomy, Ghent University, Ghent, Belgium
1 shared publicationBernard Thienpont
Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Belgium
1 shared publicationBo Goovaerts
Laboratory of Physiopharmacology, GENCOR, University of Antwerp, Antwerp, Belgium; Consortium of Excellence Infla-Med, University of Antwerp, Antwerp Belgium
1 shared publication
Latest Publications
- 5 May 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (11) , e3003-e3015
ERBB4 activation as a new therapy for atrial remodeling and fibrillation
- 5 May 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (11) , e3003-e3015
ERBB4 activation as a new therapy for atrial remodeling and fibrillation
- Open Access
- 4 October 2025
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 85, 102581
Immune cell subtype contributions to doxorubicin cardiotoxicity–defining immune targets for translational interventions
- 4 October 2025
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 85, 102581
Open AccessImmune cell subtype contributions to doxorubicin cardiotoxicity–defining immune targets for translational interventions
- 13 June 2024
- Published by University of Antwerp
Activation of ErbB4 attenuates atrial fibrillation in mice
- 13 June 2024
- Published by University of Antwerp
Activation of ErbB4 attenuates atrial fibrillation in mice
- 1 July 2021
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 14 (7) , 788-799
ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy
Background: Peripartum cardiomyopathy (PPCM) is a life-threatening disease in women without previously known cardiovascular disease. It is characterized by a sudden onset of heart failure before or after delivery. Previous studies revealed that the generation of a 16-kDa PRL (prolactin) metabolite, the subsequent upregulation of miR-146a, and the downregulation of the target gene Erbb4 is a common driving factor of PPCM. Methods: miRNA profiling was performed in plasma of PPCM patients (n=33) and postpartum-matched healthy CTRLs (controls; n=36). Elevated miRNAs in PPCM plasma, potentially targeting ERBB4 (erythroblastic leukemia viral oncogene homolog 4), were overexpressed in cardiomyocytes using lentiviral vectors. Next, cardiac function, cardiac morphology, and PPCM phenotype were investigated after recurrent pregnancies of HZ (heterozygous) cardiomyocyte-specific Erbb4 mice ( Erbb4 F/+ αMHC-Cre + , n=9) with their age-matched nonpregnant CTRLs (n=9–10). Results: Here, we identify 9 additional highly conserved miRNAs (miR-199a-5p and miR-199a-3p, miR-145a-5p, miR-130a-3p, miR-135a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, and miR19b-3p) that target tyrosine kinase receptor ERBB4 and are over 4-fold upregulated in plasma of PPCM patients at the time of diagnosis. We confirmed that miR-146a, miR-199a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, miR-130a-5p, and miR-135-3p overexpression decreases ERBB4 expression in cardiomyocytes (−29% to −50%; P Erbb4 during pregnancy suffices to induce a variant of PPCM in mice, characterized by left ventricular dilatation (postpartum second delivery: left ventricular internal diameter in diastole, +19±7% versus HZ-CTRL; P P P =0.07; −27±20%, P P <0.05) but without signs of myocardial apoptosis and inflammation. Conclusions: ERBB4 is essential to protect the maternal heart from peripartum stress. Downregulation of ERBB4 in cardiomyocytes induced by multiple miRNAs in the peripartum period may be crucial in PPCM pathophysiology. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00998556.
- 1 July 2021
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 14 (7) , 788-799
ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy
Background: Peripartum cardiomyopathy (PPCM) is a life-threatening disease in women without previously known cardiovascular disease. It is characterized by a sudden onset of heart failure before or after delivery. Previous studies revealed that the generation of a 16-kDa PRL (prolactin) metabolite, the subsequent upregulation of miR-146a, and the downregulation of the target gene Erbb4 is a common driving factor of PPCM. Methods: miRNA profiling was performed in plasma of PPCM patients (n=33) and postpartum-matched healthy CTRLs (controls; n=36). Elevated miRNAs in PPCM plasma, potentially targeting ERBB4 (erythroblastic leukemia viral oncogene homolog 4), were overexpressed in cardiomyocytes using lentiviral vectors. Next, cardiac function, cardiac morphology, and PPCM phenotype were investigated after recurrent pregnancies of HZ (heterozygous) cardiomyocyte-specific Erbb4 mice ( Erbb4 F/+ αMHC-Cre + , n=9) with their age-matched nonpregnant CTRLs (n=9–10). Results: Here, we identify 9 additional highly conserved miRNAs (miR-199a-5p and miR-199a-3p, miR-145a-5p, miR-130a-3p, miR-135a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, and miR19b-3p) that target tyrosine kinase receptor ERBB4 and are over 4-fold upregulated in plasma of PPCM patients at the time of diagnosis. We confirmed that miR-146a, miR-199a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, miR-130a-5p, and miR-135-3p overexpression decreases ERBB4 expression in cardiomyocytes (−29% to −50%; P Erbb4 during pregnancy suffices to induce a variant of PPCM in mice, characterized by left ventricular dilatation (postpartum second delivery: left ventricular internal diameter in diastole, +19±7% versus HZ-CTRL; P P P =0.07; −27±20%, P P <0.05) but without signs of myocardial apoptosis and inflammation. Conclusions: ERBB4 is essential to protect the maternal heart from peripartum stress. Downregulation of ERBB4 in cardiomyocytes induced by multiple miRNAs in the peripartum period may be crucial in PPCM pathophysiology. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00998556.